+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment

  • Book

  • March 2015
  • Elsevier Science and Technology
  • ID: 3049049

The Nonhuman Primate in Drug Development and Safety Assessment is a valuable reference dedicated to compiling the latest research on nonhuman primate models in nonclinical safety assessment, regulatory toxicity testing and translational science. By covering important topics such as study planning and conduct, inter-species genetic drift, pathophysiology, animal welfare legislation, safety assessment of biologics and small molecules, immunotoxicology and much more, this book provides scientific and technical insights to help you safely and successfully use nonhuman primates in pharmaceutical toxicity testing. A comprehensive yet practical guide, this book is intended for new researchers or practicing toxicologists, toxicologic pathologists and pharmaceutical scientists working with nonhuman primates, as well as graduate students preparing for careers in this area.

Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.

Table of Contents

Section I: Genetics of Nonhuman Primate Species Commonly Used in Drug Development Section II: Comparative Physiology of NHP Species Used in Nonclinical Safety Assessment and Drug Development Section III: Pathophysiology of NHP Species Used in Nonclinical Safety Assessment and Drug Development Section IV: Opportunities for implementing the 3Rs in drug development and safety assessment studies using nonhuman primates Section V: The Role of NHP in Safety Assessment/Regulatory Toxicology Section VI: Translational Aspects for the Use of NHP in Drug Development Section VII: NHP-Specific Aspects of Standard Toxicology Studies Section VIII: Special Toxicity Testing with NHP Section IX: Future Trends in Primate Toxicology

Authors

Joerg Bluemel PhD, ERT, Associate DIrector of Development Toxicology, Safety Assessment, Genentech, Inc., San Fransisco, CA. Sven Korte PhD, ERT, Senior Study Director, Covance Laboratories GmbH, Münster, Germany. Emanuel Schenck Dr. med. vet. PhD, Head of Pathology, MedImmune, Gaithersburg, MD. Gerhard Weinbauer PhD, Global Science Leader, Developmental and Reproductive Toxicology, Covance Laboratories GmbH, Münster, Germany.